On November 15, 2024, Evergreen Therapeutics and JUXIAN Pharmaceutical, announced the establishment of a long-term strategic cooperation. This strategic partnership signifies a deep collaboration between the two parties in the field of drug development. With the expertise in artificial intelligence, pharmaceuticals, and clinical technology, Evergreen Therapeutics will provide comprehensive support for JUXIAN Pharmaceutical's new drug development. This collaboration will not only accelerate the development process of new drugs but also promote continuous innovation in the field of innovative drugs. The collaboration between the two parties will further enhance the enhance the precision of drug development, improve the efficiency and success rate of drug development, and bring more high-quality treatment options to patients.
Chairman Juxian Wang of JUXIAN Pharmaceutical (right) and Chairman Tom Du of Evergreen Therapeutics (left) sign the cooperation agreement at the headquarters of JUXIAN Pharmaceutical.
Juxian Wang, Chairman of JUXIAN Pharmaceutical stated, "The cooperation with Evergreen Therapeutics marks an important step in our company's intelligent transformation and comprehensive strength enhancement. We look forward to strengthening technical exchanges and leveraging the synergistic advantages of both parties to tackle technical challenges. We are committed to innovation-driven development and talent cultivation, aiming to develop more innovative drugs to benefit patients."
Tom Du, MD, Chairman of Evergreen Therapeutics said, "Evergreen has been dedicated to applying AI technology to improve the efficiency and success rate of clinical drug development, which has been very well verified by our self-developed pipeline. The company's multiple new molecular pipelines have been successfully approved by the U.S. FDA for clinical trials. We look forward to joining hands with JUXIAN Pharmaceutical to promote the application of AI technology in drug development and efficiently develop innovative drugs that can fulfill the unmet clinical needs."
This strategic cooperation is based on the common strategic goals and values of both parties, aiming to achieve mutual benefits and win-win outcomes through complementary advantages. In the future, both parties will continue to deepen their cooperation and explore more cooperation opportunities in various fields, and to make joint contribution to the development of China's biopharmaceutical industry.
About JUXIAN Pharmaceutical:
JUXIAN Pharmaceutical was established in 2009, which covers scientific research, production, and sales. The company has complete production workshops and advanced production facilities and equipment, as well as a drug testing center and a drug research and development center. Through recent years of technological transformation, JUXIAN Pharmaceutical has made significant progress in the research and development of medicine, with 20 excellent products approved and launched in the market.
About Evergreen Therapeutics:
Evergreen Therapeutics is an innovative pharmaceutical company focusing on the development and application of AI technology in the fields of biology and clinical research, with branches in Shenzhen, Yantai, China and Maryland, US. The international team consists of top talents from AI pharmaceutical-related fields such as clinical medicine, international regulatory, chemistry, and computational science. The company adopts a "self-research + service" dual-business model system, engaging in differentiated in-house pipeline development in the fields of ophthalmology, vascular, and autoimmune diseases; while in other therapeutic areas, the company relies on its unique AI drug research and development platform, comprehensive capabilities in pharmaceutical regulations and clinical experience, to help customers and partners to solve the difficulties during drug development in a full stack manner, and provides flexible and efficient research and development solutions.
